Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
Provided By GlobeNewswire
Last update: Mar 13, 2025
The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals
Post-merger the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™
Read more at globenewswire.comNYSE:RFL (12/3/2025, 7:00:00 PM)
1.25
+0.02 (+1.63%)
Find more stocks in the Stock Screener
